NCT01628094View on ClinicalTrials.gov

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Hepatitis C, Chronic

Interventions

DRUG

RO5024048

DRUG

RO5190591

DRUG

RO5466731

DRUG

ribavirin [Copegus]

DRUG

ritonavir

Trial Locations (31)

1010

Grafton

2050

Sydney

2145

Westmead

3052

Parkville

4029

Herston

9016

Dunedin

13353

Berlin

20099

Hamburg

28801

Asheville

30060

Marietta

30625

Hanover

33143

South Miami

48202

Detroit

60590

Frankfurt am Main

60637

Chicago

63104

Saint Louise

66160

Kansas City

75246

Dallas

77030

Houston

78215

San Antonio

78234

San Antonio

80113

Englewood

92037

La Jolla

96813

Honolulu

98664

Vancouver

Unknown

Kingswood

Hamilton

15-540

Bialystok

41-500

Chorzów

91-357

Lodz

41-400

Mysłowice

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01628094 - ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment | Biotech Hunter | Biotech Hunter